Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Revenue projections:

Revenue projections for EW
Revenue projections for EW

With EW's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 3.716000
forwardPE 24.556932
debtToEquity 6.824000
earningsGrowth -0.766000
revenueGrowth 0.133000
grossMargins 0.780110
operatingMargins 0.237000
trailingEps 1.810000
forwardEps 3.320040

EW's current ratio of 3.716 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that EW is financially well-prepared to meet its liabilities without difficulty.
EW's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
EW's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for EW's future profitability.
Positive gross and operating margins for EW demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
With a forward EPS greater than its trailing EPS, EW is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for EW
Price projections for EW

Throughout its recent performance, EW's price has been consistently close to the lower range of projected values. This suggests that the company may face challenges in achieving higher valuations in the eyes of investors.

Insider Transactions:

Insider Transactions for EW
Insider Transactions for EW


33 Edwards Lifesciences Corporation sales were executed, with market price at 78.26151529947917.During the review period, no sell transactions were executed.Edwards Lifesciences Corporation has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Recommendations trend for EW
Recommendations trend for EW


Analysts have shown a buy bias for EW, marking it as a favorable investment option. This could inspire investors to see EW as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.